Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Hartmut Döhner, Prof. Dr.
Department of Internal Medicine III, University of Ulm
Germany: Federal Institute for Drugs and Medical Devices